Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review of the last decade-Reference-Cited by-同舟云学术

Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review of the last decade

Published:2024-08-03 Issue: Volume: Page:
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Zhou Jiawei,Zhao Guo,Wang Shuhang,Li Ning^ORCID

Funder

National Natural Science Foundation of China

CAMS | Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41416-024-02795-4.pdf

Reference62 articles.

1. Ullah A, Ahmed A, Lee KT, Yasinzai AQK, Lewis JS. Salivary gland adenoid cystic carcinoma in the U.S population: importance of grade, site of metastases, and adjuvant radiation for survival. Am J Otolaryngol. 2024;45:104266.

2. Anderson JN Jr, Beenken SW, Crowe R, Soong SJ, Peters G, Maddox WA, et al. Prognostic factors in minor salivary gland cancer. Head Neck. 1995;17:480–6.

3. Renehan A, Gleave EN, Hancock BD, Smith P, McGurk M. Long-term follow-up of over 1000 patients with salivary gland tumours treated in a single centre. Br J Surg. 1996;83:1750–4.

4. Emerick C, Mariano FV, Vargas PA, Nor JE, Squarize CH, Castilho RM. Adenoid cystic carcinoma from the salivary and lacrimal glands and the breast: Different clinical outcomes to the same tumor. Crit Rev Oncol Hematol. 2022;179:103792.

5. Nightingale J, Lum B, Ladwa R, Simpson F, Panizza B. Adenoid cystic carcinoma: a review of clinical features, treatment targets and advances in improving the immune response to monoclonal antibody therapy. Biochim Biophys Acta Rev Cancer. 2021;1875:188523.